

Special Issue

PRRSV Vaccinology and Immunology

Message from the Guest Editors

Almost 30 years have elapsed since the first PRRSV strain was successfully isolated and propagated in cell culture. Much has been learned about the virus' biology and pathogenesis, and its interaction with the host. A number of vaccines against PRRSV have been made available. Regional efforts to eradicate the virus from the swine herds have been attempted. Despite this significant progress, PRRSV remains one of the most economically important viral pathogens affecting swine production worldwide. The scope of this Special Issue focuses on the recent findings on the efficacy of PRRS vaccines under experimental and production conditions, the influence of vaccines on virus transmission and evolution within a swine herd, the host immune response to a wild-type virus infection or vaccination, and the rationale of the design of a new generation of vaccines with improved levels of safety and efficacy.

Guest Editors

Dr. Hiep Vu

Nebraska Center for Virology and Department of Animal Science,
University of Nebraska-Lincoln, Lincoln, NE 68583, USA

Prof. Dr. Asit Pattnaik

School of Veterinary and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA

Deadline for manuscript submissions

closed (30 June 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/52080

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

